文献速递骨软组织肉瘤与黑色素瘤

延长随访证实帕博利珠单抗辅助治疗高危III期黑色素瘤的无复发生存获益:EORTC 1325-MG/KEYNOTE-054试验更新结果

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial.
PubMed 文献 · J Clin Oncol · 2020-09-18

该III期双盲试验纳入1019例完全淋巴结清扫后的高危III期黑色素瘤患者,随机接受帕博利珠单抗200 mg每3周共1年或安慰剂。中位随访3.05年时,帕博利珠单抗组3年无复发生存率为63.7%,安慰剂组为44.1%(HR 0.56,95%CI 0.47-0.68),PD-L1阳性亚组HR 0.57(99%CI 0.43-0.74),各亚组获益一致。

要点

  • 帕博利珠单抗辅助治疗显著延长高危III期黑色素瘤的无复发生存。
  • 3年无复发生存率63.7% vs 44.1%,HR 0.56(95%CI 0.47-0.68)。
  • PD-L1阳性及BRAF突变等亚组中获益一致。

核心结论

  • 在完全切除的高危III期黑色素瘤中,帕博利珠单抗辅助治疗在中位随访3.05年时提供了持续且具有临床意义的无复发生存改善。

研究设计与样本

  • III期双盲随机对照试验(EORTC 1325/KEYNOTE-054),纳入1019例AJCC-7 IIIA(至少一个淋巴结转移>1 mm)、IIIB或IIIC(无移行转移)皮肤黑色素瘤且已完成淋巴结清扫的患者。
  • 患者随机接受帕博利珠单抗200 mg固定剂量(n=514)或安慰剂(n=505),每3周一次,共1年或直至疾病复发或不可接受毒性。
  • 共同主要终点为总体人群和PD-L1阳性肿瘤患者的无复发生存。

主要发现

  • 帕博利珠单抗组发生190例RFS事件,安慰剂组283例。
  • 总体人群3年RFS率:帕博利珠单抗组63.7%,安慰剂组44.1%;HR 0.56(95%CI 0.47-0.68)。
  • PD-L1阳性肿瘤亚组HR 0.57(99%CI 0.43-0.74)。
  • BRAF V600E/K突变型HR 0.51(99%CI 0.36-0.73),野生型HR 0.66(99%CI 0.46-0.95)。
  • 按AJCC-7和AJCC-8分期等亚组分析中,帕博利珠单抗对RFS的影响相似。

关键数值与推荐

  • 帕博利珠单抗200 mg每3周一次,共1年。
  • 总体人群3年RFS率63.7% vs 44.1%,HR 0.56(95%CI 0.47-0.68)。
  • PD-L1阳性亚组HR 0.57(99%CI 0.43-0.74)。

临床怎么用

  • 对于完全切除的高危III期黑色素瘤患者,可考虑帕博利珠单抗200 mg每3周辅助治疗1年。
  • 治疗决策时可参考PD-L1状态和BRAF突变状态,但各亚组均显示获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We conducted the phase III double-blind European Organisation for Research and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial to evaluate pembrolizumab versus placebo in patients with resected high-risk stage III melanoma. On the basis of 351 recurrence-free survival (RFS) events at a 1.25-year median follow-up, pembrolizumab prolonged RFS (hazard ratio [HR], 0.57; P < .0001) compared with placebo. This led to the approval of pembrolizumab adjuvant treatment by the European Medicines Agency and US Food and Drug Administration. Here, we report an updated RFS analysis at the 3.05-year median follow-up. PATIENTS AND METHODS: A total of 1,019 patients with complete lymph node dissection of American Joint Committee on Cancer Staging Manual (seventh edition; AJCC-7), stage IIIA (at least one lymph node metastasis > 1 mm), IIIB, or IIIC (without in-transit metastasis) cutaneous melanoma were randomly assigned to receive pembrolizumab at a flat dose of 200 mg (n = 514) or placebo (n = 505) every 3 weeks for 1 year or until disease recurrence or unacceptable toxicity. The two coprimary end points were RFS in the overall population and in those with programmed death-ligand 1 (PD-L1)-positive tumors. RESULTS: Pembrolizumab (190 RFS events) compared with placebo (283 RFS events) resulted in prolonged RFS in the overall population (3-year RFS rate, 63.7% v 44.1% for pembrolizumab v placebo, respectively; HR, 0.56; 95% CI, 0.47 to 0.68) and in the PD-L1-positive tumor subgroup (HR, 0.57; 99% CI, 0.43 to 0.74). The impact of pembrolizumab on RFS was similar in subgroups, in particular according to AJCC-7 and AJCC-8 staging, and BRAF mutation status (HR, 0.51 [99% CI, 0.36 to 0.73] v 0.66 [99% CI, 0.46 to 0.95] for V600E/K v wild type). CONCLUSION: In resected high-risk stage III melanoma, pembrolizumab adjuvant therapy provided a sustained and clinically meaningful improvement in RFS at 3-year median follow-up. This improvement was consistent across subgroups.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Eggermont AMM, Blank CU, Mandala M, et al. Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. J Clin Oncol. 2020. PMID: 32946353. doi:10.1200/JCO.20.02110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。